{"id":17247,"date":"2021-11-30T08:39:07","date_gmt":"2021-11-30T07:39:07","guid":{"rendered":"http:\/\/mabdesign.fr\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/"},"modified":"2021-11-30T08:39:07","modified_gmt":"2021-11-30T07:39:07","slug":"aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/","title":{"rendered":"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology"},"content":{"rendered":"
\n
\n
\n

Villejuif and Castres, France, November 18th, 2021 <\/strong><\/em>\u2013 Ribonexus (previously Aglaia Therapeutics), a biotechnology startup developing promising new therapies that can overcome resistance to current targeted therapies in cancer patients, and French pharmaceutical group Pierre Fabre<\/strong> today announce the signing of an exclusive license agreement on a series of Pierre Fabre patented small molecules targeting the Eukaryotic translation initiation factor 4A (eIF4A). This target is highly expressed in a variety of solid and hematologic cancers, including melanoma, and associated with resistance to many current therapies. Inhibiting eIF4A appears therefore to be a promising therapeutic approach.<\/p>\n

In return for the license rights granted to Ribonexus, Pierre Fabre will receive development and sales milestones payments and royalties on future sales. Financial details are not disclosed.<\/p>\n

To foster its pre-clinical development program, Ribonexus will benefit from Pierre Fabre\u2019s knowledge and support on the pharmacology and chemistry of the licensed molecules.<\/p>\n

Read more<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32],"tags":[],"class_list":["post-17247","post","type-post","status-publish","format-standard","hentry","category-news","category-our-members"],"yoast_head":"\nAglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology - MabDesign<\/title>\n<meta name=\"description\" content=\"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-30T07:39:07+00:00\" \/>\n<meta name=\"author\" content=\"alexis.mathias@kairios.fr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"alexis.mathias@kairios.fr\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/\"},\"author\":{\"name\":\"alexis.mathias@kairios.fr\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\"},\"headline\":\"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology\",\"datePublished\":\"2021-11-30T07:39:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/\"},\"wordCount\":173,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/\",\"name\":\"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"datePublished\":\"2021-11-30T07:39:07+00:00\",\"description\":\"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\",\"name\":\"alexis.mathias@kairios.fr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"caption\":\"alexis.mathias@kairios.fr\"},\"sameAs\":[\"http:\/\/mabdesign.fr\"],\"url\":\"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology - MabDesign","description":"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/","og_locale":"en_US","og_type":"article","og_title":"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology - MabDesign","og_description":"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology","og_url":"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/","og_site_name":"MabDesign","article_published_time":"2021-11-30T07:39:07+00:00","author":"alexis.mathias@kairios.fr","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"alexis.mathias@kairios.fr","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/"},"author":{"name":"alexis.mathias@kairios.fr","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135"},"headline":"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology","datePublished":"2021-11-30T07:39:07+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/"},"wordCount":173,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/","url":"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/","name":"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"datePublished":"2021-11-30T07:39:07+00:00","description":"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/aglaia-therapeutics-becomes-ribonexus-and-signs-exclusive-license-agreement-with-pierre-fabre-on-small-molecules-targeting-eif4a-an-innovative-target-in-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135","name":"alexis.mathias@kairios.fr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","caption":"alexis.mathias@kairios.fr"},"sameAs":["http:\/\/mabdesign.fr"],"url":"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17247","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=17247"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17247\/revisions"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=17247"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=17247"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=17247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}